

# **DIFLUCAN<sup>®</sup>**

## **(Fluconazole)**

### **1. NAME OF THE MEDICINAL PRODUCT**

DIFLUCAN<sup>®</sup>

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

DIFLUCAN<sup>®</sup> contains as its active ingredient fluconazole 50 mg, 150 mg and 200 mg as capsules and as 2 mg/ml in a saline solution for intravenous infusion.

### **3. PHARMACEUTICAL FORM**

Capsules, solution for intravenous infusion.

### **4. CLINICAL PARTICULARS**

#### **4.1. THERAPEUTIC INDICATIONS**

Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.

1. Cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g., pulmonary, cutaneous). Normal hosts and patients with AIDS, organ transplants or other causes of immunosuppression may be treated. DIFLUCAN<sup>®</sup> can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS.<sup>1-8</sup>
2. Systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidal infections. These include infections of the peritoneum, endocardium, eye, and pulmonary and urinary tracts. Patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated.<sup>9-13</sup>
3. Mucosal candidiasis. These include oropharyngeal, esophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). Normal hosts and patients with compromised immune function may be treated. Prevention of relapse of oropharyngeal candidiasis in patients with AIDS.<sup>14-22</sup>
4. Genital candidiasis. Vaginal candidiasis, acute or recurrent, and prophylaxis to reduce the incidence of recurrent vaginal candidiasis (three or more episodes a year). Candidal balanitis.<sup>23-35</sup>
5. Prevention of fungal infections in patients with malignancy who are predisposed to such infections as a result of cytotoxic chemotherapy or radiotherapy.<sup>36,37</sup>
6. Dermatomycosis, including tinea pedis, tinea corporis, tinea cruris, tinea versicolor, tinea unguium (onychomycosis), and dermal *Candida* infections.<sup>38-44</sup>

7. Deep endemic mycoses in immunocompetent patients, coccidioidomycosis, paracoccidioidomycosis, sporotrichosis and histoplasmosis.<sup>45</sup>

## 4.2. POSOLOGY AND METHOD OF ADMINISTRATION

The daily dose of DIFLUCAN<sup>®</sup> should be based on the nature and severity of the fungal infection. Most cases of vaginal candidiasis respond to single-dose therapy. Therapy for those types of infections requiring multiple-dose treatment should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal candidiasis usually require maintenance therapy to prevent relapse.

In the dosing instructions below, the daily dose of DIFLUCAN<sup>®</sup> is the same for oral (capsules) and intravenous administration since oral absorption is rapid and almost complete.<sup>150</sup>

### Use in Adults

1. For cryptococcal meningitis and cryptococcal infections at other sites, the usual dose is 400 mg on the first day followed by 200 mg to 400 mg once daily. Duration of treatment for cryptococcal infections will depend on the clinical and mycological response, but is usually at least 6 to 8 weeks for cryptococcal meningitis.<sup>1-8</sup>

For the prevention of relapse of cryptococcal meningitis in patients with AIDS, after the patient receives a full course of primary therapy, DIFLUCAN<sup>®</sup> may be administered indefinitely at once<sup>243</sup> daily dose of 200 mg.<sup>1-8</sup>

2. For candidemia, disseminated candidiasis and other invasive candidal infections, the usual dose is 400 mg on the first day followed by 200 mg once<sup>243</sup> daily. Depending on the clinical response, the dose may be increased to 400 mg once<sup>243</sup> daily. Duration of treatment is based upon the clinical response.<sup>9-13</sup>
3. For oropharyngeal candidiasis, the usual dose is 50 mg to 100 mg once daily for 7 to 14 days. If necessary, treatment can be continued for longer periods in patients with severely compromised immune function. For atrophic oral candidiasis associated with dentures, the usual dose is 50 mg once daily for 14 days administered concurrently with local antiseptic measures to the denture.<sup>14-22</sup>

For other candidal infections of mucosa except genital candidiasis (see below) (e.g., esophagitis, non-invasive bronchopulmonary infections, candiduria, mucocutaneous candidiasis, etc.), the usual effective dose is 50 mg to 100 mg once<sup>243</sup> daily, given for 14 to 30 days.<sup>14-22</sup>

For the prevention of relapse of oropharyngeal candidiasis in patients with AIDS, after the patient receives a full course of primary therapy, DIFLUCAN<sup>®</sup> may be administered at a 150 mg once-weekly dose.<sup>14-22</sup>

4. For the treatment of vaginal candidiasis, DIFLUCAN<sup>®</sup> 150 mg should be administered as a single oral dose.<sup>23-35</sup>

To reduce the incidence of recurrent vaginal candidiasis, a 150 mg once-monthly dose may be used. The duration of therapy should be individualized, but ranges from 4 to 12 months. Some patients may require more frequent dosing.<sup>23-35</sup>

For *Candida* balanitis, DIFLUCAN<sup>®</sup> 150 mg should be administered as a single oral dose.<sup>23-35</sup>

5. The recommended DIFLUCAN<sup>®</sup> dosage for the prevention of candidiasis is 50 mg to 400 mg once daily, based on the patient's risk for developing fungal infection. For patients at high risk of systemic infection, e.g., patients who are anticipated to have profound or prolonged neutropenia, the recommended daily dose is 400 mg once daily. DIFLUCAN<sup>®</sup> administration should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 1000 cells/mm<sup>3</sup>.<sup>36,37</sup>
6. For dermal infections including tinea pedis, tinea corporis, tinea cruris and *Candida* infections, the recommended dosage is 150 mg once weekly or 50 mg once daily. Duration of treatment is normally 2 to 4 weeks, but tinea pedis may require treatment for up to 6 weeks.<sup>38-40</sup>

For tinea versicolor, the recommended dose is 300 mg once weekly for 2 weeks; a third weekly dose of 300 mg may be needed in some patients, whereas, in some patients, a single dose of 300 mg to 400 mg may be sufficient. An alternate dosing regimen is 50 mg once daily for 2 to 4 weeks.<sup>41-44</sup>

For tinea unguium, the recommended dosage is 150 mg once weekly. Treatment should be continued until infected nail is replaced (uninfected nail grows in). Re-growth of fingernails and toenails normally requires 3 to 6 months and 6 to 12 months, respectively. However, growth rates may vary widely in individuals, and by age. After successful treatment of long-term chronic infections, nails occasionally remain disfigured.<sup>38-40</sup>

7. For deep endemic mycoses, doses of 200 mg to 400 mg once<sup>243</sup> daily for up to 2 years may be required. The duration of therapy should be individualized but ranges from 11 to 24 months with coccidioidomycosis, 2 to 17 months with paracoccidioidomycosis, 1 to 16 months with sporotrichosis and 3 to 17 months for histoplasmosis.<sup>45</sup>

### Use in Children

As with similar infections in adults, the duration of treatment is based on the clinical and mycological response. The maximum adult daily dosage should not be exceeded in children. DIFLUCAN<sup>®</sup> is administered as a single dose each day.<sup>46</sup>

The recommended dosage of DIFLUCAN<sup>®</sup> for mucosal candidiasis is 3 mg/kg once<sup>243</sup> daily. A loading dose of 6 mg/kg may be used on the first day to achieve steady-state levels more rapidly.<sup>46</sup>

For the treatment of systemic candidiasis and cryptococcal infections, the recommended dosage is 6 to 12 mg/kg once<sup>243</sup> daily, depending on the severity of the disease.<sup>46</sup>

For suppression of relapse of cryptococcal meningitis in children with AIDS, the recommended dose of DIFLUCAN<sup>®</sup> is 6 mg/kg once daily.<sup>153</sup>

For the prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic chemotherapy or radiotherapy, the dose should be 3 mg/kg to 12 mg/kg once<sup>243</sup> daily, depending on the extent and duration of the induced neutropenia (see Use in Adults). (For children with impaired renal function, see Use in Renal Impairment).<sup>46</sup>

### Use in Children 4 Weeks of Age and Younger

Neonates excrete DIFLUCAN<sup>®</sup> slowly. In the first 2 weeks of life, the same mg/kg dosing as in older children should be used but administered every 72 hours. During Weeks 3 and 4 of life, the same dose should be given every 48 hours.<sup>46</sup>

### Use in Elderly

Where there is no evidence of renal impairment, normal dosage recommendations should be adopted. For patients with renal impairment (creatinine clearance <50 ml/min), the dosage schedule should be adjusted as described below.<sup>47</sup>

### Use in Renal Impairment

DIFLUCAN<sup>®</sup> is predominantly excreted in the urine as unchanged drug. No adjustments in single-dose therapy are necessary. In patients (including children) with impaired renal function who will receive multiple doses of DIFLUCAN<sup>®</sup>, an initial loading dose of 50 mg to 400 mg should be given. After the loading dose, the daily dose (according to indication) should be administered as outlined in Table 1:<sup>47</sup>

**Table 1: Daily Dose**

| <u>Creatinine Clearance (ml/min)</u> | <u>Recommended Dose (%)</u>                |
|--------------------------------------|--|
| >50                                  | 100  |
| ≤50 (no dialysis)                    | 50   |
| Hemodialysis <sup>241</sup>          | 100 after each Hemodialysis <sup>241</sup> |

Patients on hemodialysis<sup>241</sup> should receive 100% of the recommended dose after each hemodialysis<sup>241</sup>; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance.<sup>221</sup>

### Administration

DIFLUCAN<sup>®</sup> may be administered either orally (Capsules)<sup>243</sup> or by intravenous infusion (Solution for Infusion)<sup>243</sup> at a rate not exceeding 10 ml/minute, the route being dependent on the clinical state of the patient.<sup>128,129,133</sup> On transferring from the intravenous to the oral route, or *vice versa*, there is no need to change the daily dosage. DIFLUCAN<sup>®</sup> is formulated in 0.9% sodium chloride solution, each 200 mg (100 ml bottle) containing 15 mmol each of Na<sup>+</sup> and Cl<sup>-</sup>. Because DIFLUCAN<sup>®</sup> is available as a dilute saline solution, in patients requiring sodium or fluid restriction, consideration should be given to the rate of fluid administration.<sup>48</sup>

## 4.3. CONTRAINDICATIONS

Fluconazole should not be used in patients with known sensitivity to the drug, any of the inert ingredients or to related azole compounds.

Co-administration of terfenadine is contraindicated in patients receiving fluconazole at multiple doses of 400 mg/day or higher based upon results of a multiple-dose interaction study. Co-administration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as cisapride, astemizole, erythromycin, pimozide and quinidine are contraindicated in patients receiving fluconazole<sup>49,50,51,52,152,155,162,218,219</sup> (see sections 4.4. **Special warnings and precautions for use** and 4.5. **Interaction with other medicinal products and other forms of interaction**).

#### 4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Use in pregnancy should be avoided except in patients with severe or potentially life-threatening fungal infections in whom fluconazole may be used if the anticipated benefit outweighs the possible risk to the fetus.<sup>154</sup>

Effective contraceptive measures should be considered in women of child-bearing potential and should continue throughout the treatment period and for approximately 1 week (5 to 6 half-lives) after the final dose.<sup>154</sup> (See section **4.6 Fertility, pregnancy and lactation**.) Fluconazole should be administered with caution to patients with liver dysfunction.<sup>156,157,158,159,160,218</sup>

Fluconazole has been associated with rare cases of serious hepatic toxicity including fatalities, primarily in patients with serious underlying medical conditions. In cases of fluconazole-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of patient has been observed. Fluconazole hepatotoxicity has usually been reversible on discontinuation of therapy. Patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more serious hepatic injury. Fluconazole should be discontinued if clinical signs or symptoms consistent with liver disease develop that may be attributable to fluconazole.<sup>53,54</sup>

Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole. AIDS patients are more prone to the development of severe cutaneous reactions to many drugs. If a rash, which is considered attributable to fluconazole, develops in a patient treated for a superficial fungal infection, further therapy with this agent should be discontinued. If patients with invasive/systemic fungal infections develop rashes, they should be monitored closely and fluconazole discontinued if bullous lesions or erythema multiforme develop.<sup>55,56</sup>

The co-administration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored<sup>49,50</sup> (see sections **4.3. Contraindications** and **4.5. Interaction with other medicinal products and other forms of interaction**).

In rare cases, as with other azoles, anaphylaxis has been reported.<sup>57-59</sup>

Some azoles, including fluconazole, have been associated with prolongation of the QT interval on the electrocardiogram. Fluconazole causes QT prolongation via the inhibition of Rectifier Potassium Channel current (I<sub>Kr</sub>). The QT prolongation caused by other medicinal products (such as amiodarone) may be amplified via the inhibition of cytochrome P450 (CYP) 3A4 (see section **4.5 Interaction with other medicinal products and other forms of interaction**).<sup>243</sup> During post-marketing surveillance, there have been very rare cases of QT prolongation and *torsade de pointes* in patients taking fluconazole. These reports included seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities and concomitant medications that may have been contributory.<sup>147</sup> Patients with hypokalemia and advanced cardiac failure are at an increased risk for the occurrence of life-threatening ventricular arrhythmias and *torsades de pointes*.<sup>243</sup>

Fluconazole should be administered with caution to patients with these potentially proarrhythmic conditions.<sup>147</sup>

Fluconazole should be administered with caution to patients with renal dysfunction<sup>161</sup> (see section **4.2. Posology and method of administration**).

Fluconazole is a moderate<sup>241</sup> CYP2C9 inhibitor and a moderate CYP3A4 inhibitor. Fluconazole is also an inhibitor of the isoenzyme CYP2C19.<sup>241</sup> Fluconazole-treated patients who are concomitantly treated with

drugs with a narrow therapeutic window metabolized through CYP2C9, CYP2C19 and CYP3A4 should be monitored<sup>162,238</sup> (see section **4.5. Interaction with other medicinal products and other forms of interaction**).

Adrenal insufficiency has been reported in patients receiving other azoles (e.g., ketoconazole).

Reversible cases of adrenal insufficiency were reported in patients receiving fluconazole.<sup>241</sup>

DIFLUCAN<sup>®</sup> capsules contain lactose and should not be given to patients with rare hereditary problems of galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption.<sup>163,218</sup>

#### **4.5. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION**

##### **Concomitant use of the following other medicinal products is contraindicated:**

**Cisapride:** There have been reports of cardiac events including *torsade de pointes* in patients to whom fluconazole and cisapride were co-administered. A controlled study found that concomitant treatment with fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. Concomitant treatment with fluconazole and cisapride is contraindicated in patients receiving fluconazole<sup>51,52,149</sup> (see section **4.3. Contraindications**).

**Terfenadine:** Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200 mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400 mg and 800 mg daily dose of fluconazole demonstrated that fluconazole taken in doses of 400 mg/day or greater significantly increases plasma levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated (see section **4.3. Contraindications**). The co-administration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.<sup>49,50</sup>

**Astemizole:** Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole. Resulting increased plasma concentrations of astemizole can lead to QT prolongation and rare occurrences of *torsade de pointes*. Co-administration of fluconazole and astemizole is contraindicated<sup>95</sup> (see section **4.3. Contraindications**).

**Pimozide:** Although not studied *in vitro* or *in vivo*, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of *torsade de pointes*. Co-administration of fluconazole and pimozide is contraindicated<sup>166</sup> (see section **4.3. Contraindications**).

**Quinidine:** Although not studied *in vitro* or *in vivo*, concomitant administration of fluconazole with quinidine may result in inhibition of quinidine metabolism. Use of quinidine has been associated with QT prolongation and rare occurrences of *torsades de pointes*. Co-administration of fluconazole and quinidine is contraindicated<sup>220</sup> (see section **4.3. Contraindications**).

**Erythromycin:** Concomitant use of fluconazole and erythromycin has the potential to increase the risk of cardiotoxicity (prolonged QT interval, *torsade de pointes*) and consequently sudden heart death. Co-administration of fluconazole and erythromycin is contraindicated<sup>162,219</sup> (see section **4.3. Contraindications**).

Concomitant use that should be used with caution:

**Amiodarone:** Concomitant administration of fluconazole with amiodarone may increase QT prolongation. Caution must be exercised if the concomitant use of fluconazole and amiodarone is necessary, notably with high-dose fluconazole (800 mg).<sup>243</sup>

**Lemborexant:** Concomitant administration of fluconazole increased lemborexant  $C_{max}$  and AUC by approximately 1.6- and 4.2-fold, respectively which is expected to increase risk of adverse reactions, such as somnolence. Avoid concomitant use of lemborexant.<sup>247</sup>

**Concomitant use of the following other medicinal products leads to precautions and dose adjustments:**

**The effect of other medicinal products on fluconazole**

**Hydrochlorothiazide:** In a pharmacokinetic interaction study, co-administration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentrations of fluconazole by 40%. An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics.<sup>80</sup>

**Rifampicin:** Concomitant administration of fluconazole and rifampicin resulted in a 25% decrease in the area under the concentration versus time curve (AUC) and a 20% shorter half-life of fluconazole. In patients receiving concomitant rifampicin, an increase of the fluconazole dose should be considered.<sup>87</sup>

**The effect of fluconazole on other medicinal products**

Fluconazole is a moderate inhibitor of cytochrome P450 (CYP) isoenzymes 2C9 and 3A4.<sup>241</sup> Fluconazole is also an inhibitor of the isoenzyme CYP2C19.<sup>241</sup> In addition to the observed/documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolized by CYP2C9, CYP2C19 and CYP3A4 co-administered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists 4 to 5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole<sup>162,240</sup> (see section **4.3. Contraindications**).

**Alfentanil:** A study observed a reduction in clearance and distribution volume as well as prolongation of  $t_{1/2}$  of alfentanil following concomitant treatment with fluconazole. A possible mechanism of action is fluconazole's inhibition of CYP3A4. Dosage adjustment of alfentanil may be necessary.<sup>167,218</sup>

**Amitriptyline, nortriptyline:** Fluconazole increases the effect of amitriptyline and nortriptyline. 5-Nortriptyline and/or S-amitriptyline may be measured at initiation of the combination therapy and after 1 week. Dosage of amitriptyline/nortriptyline should be adjusted, if necessary.<sup>168,169,170,171,218</sup>

**Amphotericin B:** Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic infection with *Candida albicans*, no interaction in intracranial infection with *Cryptococcus neoformans*, and antagonism of the two drugs in systemic infection with *Aspergillus fumigatus*.<sup>239</sup> The clinical significance of results obtained in these studies is unknown.<sup>172,218</sup>

**Anticoagulants:** In an interaction study, fluconazole increased the prothrombin time (12%) after warfarin administration in healthy males. In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported, in association with increases in prothrombin time in patients receiving fluconazole concurrently with

warfarin. Prothrombin time in patients receiving coumarin-type or indanedione<sup>241</sup> anticoagulants should be carefully monitored. Dose adjustment of these anticoagulants may be necessary.<sup>60-64,218,241</sup>

Azithromycin: An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 1200 mg oral dose of azithromycin on the pharmacokinetics of a single 800 mg oral dose of fluconazole as well as the effects of fluconazole on the pharmacokinetics of azithromycin. There was no significant pharmacokinetic interaction between fluconazole and azithromycin.<sup>148</sup>

Benzodiazepines (short acting): Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. If concomitant benzodiazepine therapy is necessary in patients being treated with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.<sup>65,78,79</sup>

Fluconazole increases the AUC of triazolam (single dose) by approximately 50%,  $C_{max}$  by 20% to 32% and increases  $t_{1/2}$  by 25% to 50% due to the inhibition of metabolism of triazolam. Dosage adjustments of triazolam may be necessary.<sup>173,175,218</sup>

Carbamazepine: Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. There is a risk of developing carbamazepine toxicity. Dosage adjustment of carbamazepine may be necessary depending on concentration measurements/effect.<sup>176,180,218</sup>

Calcium channel blockers: Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil and felodipine) are metabolized by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists. Frequent monitoring for adverse events is recommended.<sup>162,218</sup>

Celecoxib: During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg) the celecoxib  $C_{max}$  and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with fluconazole.<sup>181,218</sup>

Cyclosporin: Fluconazole significantly increases the concentration and AUC of cyclosporin. This combination may be used by reducing the dosage of cyclosporin depending on cyclosporin concentration.<sup>182,187,218</sup>

Cyclophosphamide: Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. The combination may be used while taking increased consideration to the risk of increased serum bilirubin and serum creatinine.<sup>188,218</sup>

Fentanyl: One fatal case of possible fentanyl fluconazole interaction was reported. The author judged that the patient died from fentanyl intoxication. Furthermore, in a randomized crossover study with 12 healthy volunteers, it was shown that fluconazole delayed the elimination of fentanyl significantly. Elevated fentanyl concentration may lead to respiratory depression.<sup>189,191,218</sup>

Halofantrine: Fluconazole can increase halofantrine plasma concentration due to an inhibitory effect on CYP3A4.<sup>192,218</sup>

HMG-CoA Reductase inhibitors: The risk of myopathy and rhabdomyolysis increases when fluconazole is co-administered with HMG-CoA reductase inhibitors metabolized through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin. If concomitant therapy is necessary,



the patient should be observed for symptoms of myopathy and rhabdomyolysis and creatine kinase should be monitored. HMG-CoA reductase inhibitors should be discontinued if a marked increase in creatine kinase is observed or myopathy/rhabdomyolysis is diagnosed or suspected.<sup>176,193-198,200,218,239</sup>

Ibrutinib: Moderate inhibitors of CYP3A4 such as fluconazole increase plasma ibrutinib concentrations and may increase risk of toxicity. If the combination cannot be avoided, reduce the dose of ibrutinib as instructed in ibrutinib prescribing information and provide close clinical monitoring.<sup>244</sup>

Losartan: Fluconazole inhibits the metabolism of losartan to its active metabolite (E-31 74) which is responsible for most of the angiotensin II-receptor antagonism which occurs during treatment with losartan. Patients should have their blood pressure monitored continuously.<sup>201,202,218,239</sup>

Methadone: Fluconazole may enhance the serum concentration of methadone. Dosage adjustment of methadone may be necessary.<sup>203-205,218</sup>

Non-steroidal anti-inflammatory drugs: The  $C_{max}$  and AUC of flurbiprofen were increased by 23% and 81%, respectively, when co-administered with fluconazole compared to administration of flurbiprofen alone. Similarly, the  $C_{max}$  and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] were increased by 15% and 82%, respectively, when fluconazole was co-administered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone.<sup>206,207,218</sup>

Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other non-steroidal anti-inflammatory drugs (NSAIDs) that are metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended. Adjustment of dosage of NSAIDs may be needed.<sup>162</sup>

Olaparib: Moderate inhibitors of CYP3A4 such as fluconazole increase olaparib plasma concentrations; concomitant use is not recommended. If the combination cannot be avoided, limit the dose of olaparib to 200 mg twice daily.<sup>242</sup>

Oral contraceptives: Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. There were no relevant effects on hormone level in the 50 mg fluconazole study, while at 200 mg daily, the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 24%, respectively. Thus, multiple-dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive.<sup>81-84</sup>

Phenytoin: Fluconazole inhibits the hepatic metabolism of phenytoin. With co-administration, serum phenytoin concentration levels should be monitored in order to avoid phenytoin toxicity.<sup>85,87</sup>

Prednisone: There was a case report that a liver-transplanted patient treated with prednisone developed acute adrenal cortex insufficiency when a 3-month therapy with fluconazole was discontinued. The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone. Patients on long-term treatment with fluconazole and prednisone should be carefully monitored for adrenal cortex insufficiency when fluconazole is discontinued.<sup>208,218</sup>

Rifabutin: There have been reports that an interaction exists when fluconazole is administered concomitantly with rifabutin, leading to increased serum levels of rifabutin up to 80%. There have been reports of uveitis in patients to whom fluconazole and rifabutin were co-administered. Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.<sup>86,209,218</sup>

Saquinavir: Fluconazole increases the AUC of saquinavir by approximately 50%,  $C_{max}$  by approximately 55% and decreases the clearance of saquinavir by approximately 50% due to inhibition of saquinavir's hepatic metabolism by CYP3A4 and inhibition of P-glycoprotein. Dosage adjustment of saquinavir may be necessary.<sup>210,211,218</sup>

Sirolimus: Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P-glycoprotein. This combination may be used with a dosage adjustment of sirolimus depending on the effect/concentration measurements.<sup>212-215,218</sup>

Sulfonylureas: Fluconazole has been shown to prolong the serum half-life of concomitantly administered oral sulfonylureas (e.g., chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy volunteers. Frequent monitoring of blood glucose and appropriate reduction of sulfonylurea dosage are recommended during co-administration.<sup>88-91,218</sup>

Tacrolimus: Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously. Increased tacrolimus levels have been associated with nephrotoxicity. Dosage of orally administered tacrolimus should be decreased depending on tacrolimus concentration.<sup>92,164,165,218</sup>

Theophylline: In a placebo-controlled interaction study, the administration of fluconazole 200 mg for 14 days resulted in an 18% decrease in the mean plasma clearance rate of theophylline. Patients who are receiving high-dose theophylline or who are otherwise at increased risk for theophylline toxicity should be observed for signs of theophylline toxicity while receiving fluconazole, and therapy modified appropriately if signs of toxicity develop.<sup>93</sup>

Tofacitinib: Exposure of tofacitinib is increased when tofacitinib is co-administered with medications that result in both moderate inhibition of CYP3A4 and inhibition of CYP2C19 (e.g., fluconazole).<sup>237,241</sup> Dosage adjustment of tofacitinib may be necessary.<sup>237,238</sup>

Tolvaptan: Exposure to tolvaptan is significantly increased (200% in AUC; 80% in  $C_{max}$ ) when tolvaptan, a CYP3A4 substrate, is co-administered with fluconazole, a moderate CYP3A4 inhibitor, with risk of significant increase in adverse effects particularly significant diuresis, dehydration and acute renal failure. In case of concomitant use, the tolvaptan dose should be reduced and the patient managed cautiously.<sup>245</sup>

Vinca alkaloids: Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an inhibitory effect on CYP3A4.<sup>162,218</sup>

Vitamin A: Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. This combination may be used but the incidence of CNS related undesirable effects should be borne in mind.<sup>216,218</sup>

Zidovudine: Fluconazole increases the  $C_{max}$  and AUC of zidovudine by 84% and 74%, respectively, due to an approximately 45% decrease in oral zidovudine clearance. The half-life of zidovudine was likewise prolonged by approximately 128% following combination therapy with fluconazole. Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions. Dosage reduction of zidovudine may be considered.<sup>94,217,218</sup>

**Voriconazole:** (CYP2C9, CYP2C19 and CYP3A4 inhibitor): Concurrent administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral fluconazole (400 mg on Day 1, then 200 mg Q24h for 4 days) to 8 healthy male subjects resulted in an increase in  $C_{max}$  and AUC $\tau$  of voriconazole by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. In a follow-on clinical study involving 8 healthy male subjects, reduced dosing and/or frequency of voriconazole and fluconazole did not eliminate or diminish this effect. Concomitant administration of voriconazole and fluconazole at any dose is not recommended.<sup>235,236,239</sup>

Interaction studies have shown that when oral fluconazole is co-administered with food, cimetidine, antacids or following total body irradiation for bone marrow transplantation, no clinically significant impairment of fluconazole absorption occurs.<sup>96-99</sup>

Physicians should be aware that drug-drug interaction studies with other medications have not been conducted, but such interactions may occur.

#### 4.6. FERTILITY, PREGNANCY AND LACTATION

##### Use During Pregnancy

Use in pregnancy should be avoided except in patients with severe or potentially life-threatening fungal infections in whom fluconazole may be used if the anticipated benefit outweighs the possible risk to the fetus.<sup>154</sup>

Effective contraceptive measures should be considered in women of child-bearing potential and should continue throughout the treatment period and for approximately 1 week (5 to 6 half-lives) after the final dose.<sup>154</sup>

There have been reports of spontaneous abortion and congenital abnormalities in infants whose mothers were treated with 150 mg of fluconazole as a single or repeated dose in the first trimester.<sup>154</sup>

There have been reports of multiple congenital abnormalities in infants whose mothers were being treated for 3 or more months with high-dose (400 mg/day to 800 mg/day) fluconazole therapy for coccidioidomycosis. The relationship between fluconazole use and these events is unclear. Adverse fetal effects have been seen in animals only at high-dose levels associated with maternal toxicity.<sup>100</sup> There were no fetal effects at 5 mg/kg or 10 mg/kg; increases in fetal anatomical variants (supernumerary ribs, renal pelvis dilation) and delays in ossification were observed at 25 mg/kg and 50 mg/kg<sup>154</sup> and higher doses. At doses ranging from 80 mg/kg (approximately 20-60 times the recommended human dose) to 320 mg/kg, embryolethality in rats was increased and fetal abnormalities included wavy ribs, cleft palate and abnormal craniofacial ossification. These effects are consistent with the inhibition of estrogen synthesis in rats and may be a result of known effects of lowered estrogen on pregnancy, organogenesis and parturition.<sup>101</sup>

Case reports describe a distinctive and a rare pattern of birth defects among infants whose mothers received high-dose (400-800 mg/day) fluconazole during most or all of the first trimester of pregnancy. The features seen in these infants include brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease.<sup>222-234</sup>

##### Use During Lactation

Fluconazole is found in human breast milk at concentrations similar to plasma (see section 5.2. **Pharmacokinetic properties**).<sup>102</sup> The elimination half-life from breast milk approximates the plasma elimination half-life of 30 hours.<sup>241</sup> The estimated daily infant dose of fluconazole from breast milk (assuming mean milk consumption of 150 ml/kg/day) based on the mean peak milk concentration is 0.39 mg/kg/day, which is approximately 40% of the recommended neonatal dose (<2 weeks of age) or 13% of the recommended infant dose for mucosal candidiasis.<sup>241</sup>

Breast-feeding may be maintained after a single dose of 150 mg fluconazole. Breast-feeding is not recommended after repeated use or after high-dose fluconazole. The developmental and health benefits of breast-feeding should be considered along with the mother’s clinical need for Diflucan and any potential adverse effects on the breastfed child from Diflucan or from the underlying maternal condition.<sup>241</sup>

**4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or seizures may occur.<sup>199,218</sup>

**4.8. UNDESIRABLE EFFECTS**

DIFLUCAN<sup>®</sup> is generally well tolerated.<sup>12,14,22,103</sup>

In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal and hematological function test results and hepatic abnormalities (see section 4.4. **Special warnings and precautions for use**) have been observed during treatment with DIFLUCAN<sup>®</sup> and comparative agents, but the clinical significance and relationship to treatment is uncertain.<sup>2,8,37,53,54,103</sup>

The following undesirable effects have been observed and reported during treatment with DIFLUCAN<sup>®</sup> with the following frequencies: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).<sup>239</sup>

| System Organ Class                          | Frequency | Undesirable Effects  |
|---|-----------|--|
| <b>Blood and lymphatic system disorders</b> | Rare      | Agranulocytosis, <sup>109</sup> leukopenia, <sup>107</sup> neutropenia, <sup>109</sup> thrombocytopenia <sup>108</sup> |
| <b>Immune system disorders</b>              | Rare      | Anaphylaxis, angioedema <sup>69,70</sup>   |
| <b>Metabolism and nutrition disorders</b>   | Rare      | Hypertriglyceridaemia, <sup>73</sup> hypercholesterolaemia, <sup>72</sup> hypokalaemia <sup>74,218</sup>               |
| <b>Psychiatric disorders</b>                | Uncommon  | Insomnia, <sup>218</sup> somnolence <sup>218</sup>   |
| <b>Nervous system disorders</b>             | Common    | Headache <sup>104</sup>  |
|   | Uncommon  | Seizures, <sup>105</sup> dizziness <sup>66</sup> , paraesthesia, <sup>218</sup> taste perversion <sup>75</sup>         |
|   | Rare      | Tremor <sup>218</sup>  |
| <b>Ear and labyrinth disorders</b>          | Uncommon  | Vertigo <sup>218</sup>   |
| <b>Cardiac disorders</b>                    | Rare      | <i>Torsade de pointes</i> , QT prolongation  |
| <b>Gastrointestinal disorders</b>           | Common    | Abdominal pain, diarrhoea, nausea, vomiting <sup>68</sup>  |

|   |           |   |
|---|-----------|---|
|   | Uncommon  | Dyspepsia, <sup>67</sup> flatulence, dry mouth <sup>218</sup>   |
| <b>Hepatobiliary disorders</b>                              | Common    | Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased  |
|   | Uncommon  | Cholestasis, <sup>218</sup> jaundice, bilirubin increased   |
|   | Rare      | Hepatic toxicity, including rare cases of fatalities, hepatic failure, hepatocellular necrosis, hepatitis, hepatocellular damage <sup>218</sup>                               |
| <b>Skin and subcutaneous tissue disorders</b>               | Common    | Rash  |
|   | Uncommon  | Pruritus, <sup>71</sup> urticaria, <sup>146</sup> increased sweating, <sup>218</sup> drug eruption <sup>a,218</sup>   |
|   | Rare      | Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis, <sup>218</sup> dermatitis exfoliative, face oedema, alopecia <sup>106</sup> |
|   | Not known | Drug reaction with eosinophilia and systemic symptoms (DRESS) <sup>241</sup>  |
| <b>Musculoskeletal and connective tissue disorders</b>      | Uncommon  | Myalgia <sup>218</sup>  |
| <b>General disorders and administration site conditions</b> | Uncommon  | Fatigue, <sup>218</sup> malaise, <sup>218</sup> asthenia, <sup>218</sup> fever <sup>218</sup>   |

<sup>a</sup> Including Fixed Drug Eruption<sup>241</sup>

### Pediatric Population

The pattern and incidence of adverse events and laboratory abnormalities recorded during pediatric clinical trials are comparable to those seen in adults.

## 4.9. OVERDOSE

There have been reports of overdose with fluconazole accompanied by hallucination and paranoid behaviour.<sup>76,77,110,218</sup>

In the event of overdosage, symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate.

Fluconazole is largely excreted in the urine; forced volume diuresis would probably increase the elimination rate. A 3-hour hemodialysis session decreases plasma levels by approximately 50%.<sup>111-114</sup>

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1. PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code J02AC01.

#### Mode of Action

Fluconazole, a triazole antifungal agent, is a potent and specific inhibitor of fungal sterol synthesis.<sup>115</sup> Its primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14-alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14-alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.<sup>246</sup>

Fluconazole is highly specific for fungal cytochrome P-450 dependent enzymes.<sup>115,119</sup> Fluconazole 50 mg daily given up to 28 days has been shown not to affect testosterone plasma concentrations in males or steroid concentrations in females of child-bearing age.<sup>81,120,121</sup> Fluconazole 200 mg to 400 mg daily has no clinically significant effect on endogenous steroid levels or on adrenocorticotrophic hormone (ACTH) stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50 mg do not affect its metabolism.<sup>122,123,246</sup>

#### Pharmacokinetic/pharmacodynamic relationship

In animal studies, there is a correlation between MIC values and efficacy against experimental mycoses due to *Candida* spp. In clinical studies, there is an almost 1:1 linear relationship between the AUC and the dose of fluconazole. There is also a direct though imperfect relationship between the AUC or dose and a successful clinical response of oral candidosis and to a lesser extent candidaemia to treatment. Similarly, cure is less likely for infections caused by strains with a higher fluconazole MIC.<sup>246</sup>

#### Microbiology

*In vitro*, fluconazole displays antifungal activity against most clinically common *Candida* species (including *C. albicans*, *C. parapsilosis*, *C. tropicalis*). MICs for *C. glabrata* and *C. guilliermondii* tend to be higher, while *C. krusei* is intrinsically resistant to fluconazole. The recently emerging species *C. auris* tends to be relatively resistant to fluconazole.<sup>246</sup>

Fluconazole also exhibits activity *in vitro* against *Cryptococcus neoformans* and *Cryptococcus gattii* as well as the endemic moulds *Blastomyces dermatitidis*, *Coccidioides immitis*, *Histoplasma capsulatum* and *Paracoccidioides brasiliensis*.<sup>246</sup>

Both orally and intravenously administered fluconazole was active in a variety of animal fungal infection models. Activity has been demonstrated against opportunistic mycoses, such as infections with *Candida* spp., including systemic candidiasis in immunocompromised animals; with *C. neoformans*, including intracranial infections; with *Microsporum* spp.; and with *Trichophyton* spp. Fluconazole has also been shown to be active in animal models of endemic mycoses, including infections with *Blastomyces dermatitidis*; with *Coccidioides immitis*, including intracranial infection; and with *Histoplasma capsulatum* in normal and immunosuppressed animals.<sup>116</sup>

#### Mechanisms of resistance

In usually susceptible species of *Candida*, the most commonly encountered mechanism of resistance involves the target enzymes of the azoles, which are responsible for the biosynthesis of ergosterol. Point mutations in the gene (*ERG11*) encoding for the target enzyme lead to an altered target with decreased affinity for azoles. Overexpression of *ERG11* results in the production of high concentrations of the target enzyme, creating the need for higher intracellular drug concentrations to inhibit all of the enzyme molecules in the cell.<sup>246</sup>

The second major mechanism of drug resistance involves active efflux of fluconazole out of the cell through the activation of two types of multidrug efflux transporters; the major facilitators (encoded by *MDR* genes) and those of the ATP-binding cassette superfamily (encoded by *CDR* genes). Upregulation of the *MDR* gene leads to fluconazole resistance, whereas, upregulation of *CDR* genes may lead to resistance to multiple azoles.<sup>246</sup>

Resistance in *Candida glabrata* usually includes upregulation of *CDR* genes resulting in resistance to multiple azoles. For an isolate where the minimum inhibitory concentration (MIC) is 16 to 32 mg/L, the highest fluconazole dose is recommended.<sup>246</sup>

There have been reports of cases of superinfection with *Candida* species other than *C. albicans*, which are often inherently not susceptible to fluconazole (e.g., *Candida krusei*). Such cases may require alternative antifungal therapy.<sup>117,118</sup>

**Breakpoints**

**EUCAST Reference Information (for markets referencing the EUCAST)**

Based on analyses of pharmacokinetic/pharmacodynamic (PK/PD) data, susceptibility *in vitro* and clinical response EUCAST AFST (European Committee on Antimicrobial Susceptibility Testing - Subcommittee on Antifungal Susceptibility Testing) has determined breakpoints for fluconazole for *Candida* species (EUCAST Fluconazole rationale document (2013) version 2; European Committee on Antimicrobial Susceptibility Testing, Antifungal Agents, Breakpoint tables for interpretation of MICs, Version 9.0, valid from 2018-02-12). These have been divided into non species related breakpoints, which have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species, and species related breakpoints for those species most frequently associated with human infection.<sup>246</sup> These breakpoints are given in the table below:

| Antifungal  | Species-related breakpoints (S≤/R>) in mg/L |                         |                       |                             |                           | Non-species related breakpoints <sup>A</sup> S≤/R> in mg/L |
|-------------|---|-------------------------|-----------------------|-----------------------------|---------------------------|--|
|             | <i>Candida albicans</i>                     | <i>Candida glabrata</i> | <i>Candida krusei</i> | <i>Candida parapsilosis</i> | <i>Candida tropicalis</i> |  |
| Fluconazole | 2/4   | 0.002/32*               | --                    | 2/4                         | 2/4                       | 2/4  |

S = Susceptible, R = Resistant

A = Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints.

-- = Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product.

\* = A significant number of infections involve *C. glabrata*, for which fluconazole MICs are 2-32 mg/L in the absence of resistance mechanisms. As there are few agents suitable for the treatment of urinary tract infections and mucosal infections managed in the primary health care setting, fluconazole may be a suitable choice. In cases where fluconazole is the only available antifungal agent for treating *C. glabrata* infections the use of a higher dosage may be required.

There is insufficient evidence that the following species are good targets for therapy with fluconazole: *C. dubliniensis*, *C. guilliermondii*.

**CLSI Reference Information (for markets referencing the CLSI)**

The susceptible (S) breakpoints recognized by the Clinical and Laboratory Standards Institute (CLSI) are the same, with the exception of *C. glabrata*, for which there is no S, but only an ‘SDD’ (susceptible dose-dependent) breakpoint of ≤32 mg/L is recognized. CLSI also characterizes 4 mg/L as SDD for *C. albicans*, *C. parapsilosis* and *C. glabrata*, and ≥8 mg/L as resistant (R) for these 3 species (Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antifungal Susceptibility Testing of Yeasts. 1st

ed. CLSI supplement M60 (ISBN 1-56238-828-2 [Print]; ISBN 1-56238-829-0 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017).<sup>246</sup>

### **FDA Reference Information (US FDA requirement for the USPI)**

The United States Food and Drug Administration (FDA) accepts the CLSI S and R breakpoints; however, it does not use the SDD terminology and considers those values as 'intermediate' (I) (<https://www.fda.gov/STIC>).<sup>246</sup>

## **5.2. PHARMACOKINETIC PROPERTIES**

The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral route.<sup>111,124,125</sup> After oral administration, fluconazole is well absorbed, and plasma levels (and systemic bioavailability) are over 90% of the levels achieved after intravenous administration.<sup>124,126</sup> Oral absorption is not affected by concomitant food intake.<sup>96</sup> Peak plasma concentrations in the fasting state occur between 0.5 and 1.5 hours post-dose with a plasma elimination half-life of approximately 30 hours.<sup>127-129</sup> Plasma concentrations are proportional to dose.<sup>120,130-132</sup> Ninety percent steady-state levels are reached by Days 4 to 5 with multiple once-daily dosing.<sup>116</sup>

Administration of loading dose (on Day 1) of twice the usual daily dose enables plasma levels to approximate to 90% steady-state levels by Day 2.<sup>133,134</sup> The apparent volume of distribution approximates to total body water.<sup>111,135</sup> Plasma protein binding is low (11%-12%).<sup>92,93,111,135,136</sup>

Fluconazole achieves good penetration in all body fluids studied.<sup>111,129</sup> The levels of fluconazole in saliva and sputum are similar to plasma levels.<sup>92,93,120,121,133-137</sup> In patients with fungal meningitis, fluconazole levels in the cerebrospinal fluid (CSF) are approximately 80% the corresponding plasma levels.<sup>1,132</sup>

High skin concentrations of fluconazole, above serum concentrations, are achieved in the stratum corneum, epidermis-dermis and eccrine sweat. Fluconazole accumulates in the stratum corneum. At a dose of 50 mg once daily, the concentration of fluconazole after 12 days was 73 µg/g, and 7 days after cessation of treatment the concentration was still 5.8 µg/g. At the 150 mg once-a-week dose, the concentration of fluconazole in stratum corneum on Day 7 was 23.4 µg/g, and 7 days after the second dose was still 7.1 µg/g.<sup>138</sup>

Concentration of fluconazole in nails after 4 months of 150 mg once-a-week dosing was 4.05 µg/g in healthy and 1.8 µg/g in diseased nails; and, fluconazole was still measurable in nail samples 6 months after the end of therapy.<sup>29</sup>

The major route of excretion is renal, with approximately 80% of the administered dose appearing in the urine as unchanged drug.<sup>125,139</sup> Fluconazole clearance is proportional to creatinine clearance. There is no evidence of circulating metabolites.<sup>112,125</sup>

The long plasma elimination half-life provides the basis for single-dose therapy for vaginal candidiasis, once-daily and once-weekly dosing for other indications.<sup>127-129</sup>

A study compared the saliva and plasma concentrations of a single fluconazole 100 mg dose administered in a capsule or in an oral suspension by rinsing and retaining in mouth for 2 minutes and swallowing. The maximum concentration of fluconazole in saliva after the suspension was observed 5 minutes after ingestion, and was 182 times higher than the maximum saliva concentration after the capsule which



occurred 4 hours after ingestion. After about 4 hours, the saliva concentrations of fluconazole were similar. The mean AUC (0-96) in saliva was significantly greater after the suspension compared to the capsule. There was no significant difference in the elimination rate from saliva or the plasma pharmacokinetic parameters for the two formulations.<sup>139</sup>

A pharmacokinetic study in 10 lactating women, who had temporarily or permanently stopped breast-feeding their infants, evaluated fluconazole concentrations in plasma and breast milk for 48 hours following a single 150 mg dose of Diflucan. Fluconazole was detected in breast milk at an average concentration of approximately 98% of those in maternal plasma. The mean peak breast milk concentration was 2.61 mg/L at 5.2 hours post-dose.

Pharmacokinetics in Children<sup>140</sup>

In children, pharmacokinetic data have been reported as follows in Table 2:

| <b>Table 2: Pharmacokinetic Data in Children</b> |                          |                          |                      |
|--|--------------------------|--------------------------|----------------------|
| <b>Age Studied</b>                               | <b>Dose (mg/kg)</b>      | <b>Half-life (hours)</b> | <b>AUC (µg·h/ml)</b> |
| 11 days –11 months                               | Single-IV 3 mg/kg        | 23.0                     | 110.1                |
| 9 months-13 years                                | Single-Oral<br>2 mg/kg   | 25.0                     | 94.7                 |
| 9 months-13 years                                | Single-Oral<br>8 mg/kg   | 19.5                     | 362.5                |
| 5 years –15 years                                | Multiple-IV<br>2 mg/kg   | 17.4*                    | 67.4*                |
| 5 years –15 years                                | Multiple-IV<br>4 mg/kg   | 15.2*                    | 139.1*               |
| 5 years –15 years                                | Multiple-IV<br>8 mg/kg   | 17.6*                    | 196.7*               |
| Mean age 7 years                                 | Multiple-Oral<br>3 mg/kg | 15.5                     | 41.6                 |
| * Denotes final day                              |                          |                          |                      |

In premature newborns (gestational age around 28 weeks), intravenous administration of fluconazole of 6 mg/kg was given every third day for a maximum of five doses while the premature newborns remained in the intensive care unit. The mean half-life (hours) was 74 (range 44-185) on Day 1, which decreased with time to a mean of 53 (range 30-131) on Days 7 and 47 (range 27-68) on Day 13.

The AUC (µg·h/ml) was 271 (range 173-385) on Day 1, which increased with a mean of 490 (range 292-734) on Day 7 and decreased with a mean of 360 (range 167-566) on Day 13.

The volume of distribution (ml/kg) was 1183 (range 1070-1470) on Day 1, which increased with time to a mean of 1184 (range 510-2130) on Day 7 and 1328 (range 1040-1680) on Day 13.

Pharmacokinetics in Elderly<sup>151</sup>

A pharmacokinetic study was conducted in 22 subjects, 65 years of age or older receiving a single 50 mg oral dose of fluconazole. Ten of these patients were concomitantly receiving diuretics. The C<sub>max</sub> was 1.54 µg/ml and occurred at 1.3 hours post dose. The mean AUC was 76.4 ± 20.3 µg h/ml, and the mean terminal half-life was 46.2 hours. These pharmacokinetic parameter values are higher than analogous values reported for normal young male volunteers. Co-administration of diuretics did not significantly

alter the AUC or  $C_{max}$ . In addition, creatinine clearance (74 ml/min), the percent of drug recovered unchanged in urine (0-24 hours, 22%) and the fluconazole renal clearance estimates (0.124 ml/min/kg) for the elderly were generally lower than those of younger volunteers. Thus, the alteration of fluconazole disposition in the elderly appears to be related to reduced renal function characteristic of this group. A plot of each subject's terminal elimination half-life versus creatinine clearance compared to the predicted half-life - creatinine clearance curve derived from normal subjects and subjects with varying degrees of renal insufficiency indicated that 21 of 22 subjects fell within the 95% confidence limit of the predicted half-life - creatinine clearance curves. These results are consistent with the hypothesis that higher values for the pharmacokinetic parameters observed in the elderly subjects compared to normal young male volunteers are due to the decreased kidney function that is expected in the elderly.

### 5.3. PRECLINICAL SAFETY DATA

#### Carcinogenesis<sup>141</sup>

Fluconazole showed no evidence of carcinogenic potential in mice and rats treated orally for 24 months at doses of 2.5, 5 or 10 mg/kg/day (approximately 2-7 times the recommended human dose). Male rats treated with 5 and 10 mg/kg/day had an increased incidence of hepatocellular adenomas.

#### Mutagenesis<sup>142,143</sup>

Fluconazole, with or without metabolic activation, was negative in tests for mutagenicity in four strains of *Salmonella typhimurium*, and in the mouse lymphoma L5178Y system.<sup>239</sup> Cytogenetic studies *in vivo* (murine bone marrow cells, following oral administration of fluconazole) and *in vitro* (human lymphocytes exposed to fluconazole at 1000 µg/ml) showed no evidence of chromosomal mutations.

#### Impairment of Fertility<sup>144,145</sup>

Fluconazole did not affect the fertility of male or female rats treated orally with daily doses of 5 mg/kg, 10 mg/kg or 20 mg/kg or with parenteral doses of 5 mg/kg, 25 mg/kg or 75 mg/kg, although the onset of parturition was slightly delayed at 20 mg/kg orally. In an intravenous perinatal study in rats at 5 mg/kg, 20 mg/kg and 40 mg/kg, dystocia and prolongation of parturition were observed in a few dams at 20 mg/kg (approximately 5-15 times the recommended human dose) and 40 mg/kg, but not at 5 mg/kg. The disturbances in parturition were reflected by a slight increase in the number of still-born pups and decrease of neonatal survival at these dose levels. The effects on parturition in rats are consistent with the species specific estrogen-lowering property produced by high doses of fluconazole. Such a hormone change has not been observed in women treated with fluconazole (see section 5.1. **Pharmacodynamic properties**).

## 6. PHARMACEUTICAL PARTICULARS

### 6.1. LIST OF EXCIPIENTS

#### Capsules

DIFLUCAN® capsules contain lactose (49.70mg in 50mg Capsule, 149.102mg in 150mg Capsule and 198.80mg in 200mg Capsule), maize starch, colloidal silicon dioxide, magnesium stearate and sodium lauryl sulphate as excipients.

#### Intravenous Infusion

DIFLUCAN<sup>®</sup> intravenous infusion is a sterile aqueous solution which is made iso-osmotic with sodium chloride.

## 6.2. INCOMPATIBILITIES

DIFLUCAN<sup>®</sup> intravenous infusion is compatible with the following administration fluids:

- a) Dextrose 20%
- b) Ringer's solution
- c) Hartmann's solution
- d) Potassium chloride in dextrose
- e) Sodium bicarbonate 4.2%
- f) Aminofusin
- g) Normal saline

DIFLUCAN<sup>®</sup> may be infused through an existing line with one of the above listed fluids. Although no specific incompatibilities have been noted, mixing with any other drug prior to infusion is not recommended.

## 6.3. SHELF-LIFE

DIFLUCAN<sup>®</sup> (fluconazole) should not be used beyond the expiry date.

- Capsules: 36 months.
- Intravenous infusion: 24 months.

## 6.4. SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

## 6.5. NATURE AND CONTENTS OF CONTAINER

### Capsules

DIFLUCAN<sup>®</sup> (fluconazole) is available in polyvinyl chloride (PVC) blister packs with aluminum foil backing in the following presentations;

- 50 mg capsules: 7s blister pack.
- 150 mg capsules: 1s blister pack.
- 200 mg capsules: 4s blister pack.

### Intravenous Infusion

DIFLUCAN<sup>®</sup> (fluconazole) intravenous infusion is available in glass vial of 50 ml.

## 6.6. SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

Capsules should be swallowed whole.

**Diflucan/LPD/PK-10**

According to CDS V 17 dated: 09-November-2020; Supersedes CDS V 16 dated: 16-April-2020

**Marketed by:**  
Pfizer Pakistan Limited

*Please visit our website [www.pfizerpro.com.pk](http://www.pfizerpro.com.pk) for latest version of Product leaflet.*

## 7. REFERENCES

1. Tucker RM, Williams PL, Arathoon EG, *et al.* Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. *Antimicrob Agents Chemother.* March 1988; 32(3):369-373.
2. Stern JJ, Hartman BJ, Sharkey P, *et al.* Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: Experience with 22 patients. *Amer J Med.* Oct 1988; 85:477-480.
3. Byrne WR, Wajszechuk CP. Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): Successful treatment with fluconazole after failure of amphotericin B. *Ann Intern Med.* March 1988; 108(3):384-385.
4. Classen DC, Burke JP, Smith CB. Treatment of coccidioidal meningitis with fluconazole. *J Infect Dis.* Oct 1988; 158(4):903-904.
5. Van't Wout JW, DeGraeff-Meeder ER, Paul LC, *et al.* Treatment of two cases of cryptococcal meningitis with fluconazole. *Scand J Infec Dis.* 1988; 20(2):193-198.
6. Fluconazole IRD. Volume 4.6. August 1988; Protocol 152. pp. 1107-1166.
7. Fluconazole IRD. Volume 4.6. August 1988; Protocol 112. pp. 1168-1186.
8. Fluconazole IRD. Volume 4.6. August 1988; Protocol 114. pp. 1351-1386.
9. Fluconazole IRD. Volume 4.4. August 1988; Protocol 343. pp. 469-498.
10. Fluconazole IRD. Volume 4.5. August 1988; Protocol 342. pp. 857-884.
11. Isalska BJ, Stanbridge TN. Fluconazole in the treatment of candidal prosthetic valve endocarditis. *British Med J.* July 16, 1988. 297(6642):178-179.
12. Van't Wout JW, Mattie H, Van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. *Antimicrobial Chemotherapy.* 1988, 21:665-672.
13. Urbak SF and Degn T. Fluconazole in the management of fungal ocular infection. *Ophthalmologica.* 1994; 208:147-156.
14. Dupont B, Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. *J Med Vet Mycol.* Feb. 1988; 26(1):67-71.
15. Fluconazole Capsules IRD. Volume 4.5. May 1987; Protocols 341 and 345. pp. 1051-1166.
16. Hay RJ, Clayton YM. Fluconazole in the management of patients with chronic mucocutaneous candidosis. *Br J Dermatol.* Nov. 1988; 119(5):683-684.
17. Drew RH, Perfect JR, Gallis HA. Use of fluconazole in a patient with documented malabsorption of ketoconazole. *Clinical Pharm.* August 1988; 7(8):622-623.
18. Fluconazole Capsules IRD. Volume 4.5. May 1987; Protocol 347. pp. 1234-1271.

19. Fluconazole Capsules IRD. Volume 4.5. May 1987; Protocol 344. pp. 1198-1233.
20. Study Report, Protocol FCA-AUS-87-003, A double-blind, placebo-controlled, multicenter study of the safety and efficacy of oral fluconazole in the prophylaxis of recurrent oropharyngeal candidiasis in AIDS patients.
21. Marriott DJE *et al.* Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. *Med J Aust* 1993; 158:312-316.
22. Study Report, Protocol 056-350, A non-comparative study to assess the efficacy, safety and toleration of fluconazole in the treatment of severe mucosal candidiasis in AIDS patients followed by a double-blind, placebo controlled evaluation of a single weekly dose of fluconazole in preventing recurrence of fungal infection.
23. Overview of Data to Support the Use of Diflucan (Fluconazole) in the Prophylaxis of Recurrent Vaginal Candidiasis.
24. Study Report, Protocol FCA-NY-86-003, A multicenter, double-blind, placebo-controlled study of once monthly single dose fluconazole in the prophylaxis of recurrent vaginal candidiasis.
25. Study Report, Protocol FCA-CDN-88-003, A multicenter, comparative, double-blind, parallel study of the safety and efficacy of single dose intermittent prophylaxis with oral fluconazole vs. placebo in recurrent vaginal candidiasis.
26. Study Report, Protocol FCA-UK-88-013, Fluconazole in recurrent vaginal candidiasis.
27. Study Report, Protocol 330, A multicenter, non-comparative study to assess the efficacy, safety and toleration of a single oral dose of fluconazole in the treatment of patients with frequently recurring vaginal candidiasis, followed by a double-blind, placebo-controlled evaluation of single dose fluconazole given monthly in preventing recurrence of vaginal candidiasis.
28. Study Report, Protocol FCA-NY-88-008, An open, non-comparative pilot study to access the efficacy and safety of a single oral dose of 150 mg fluconazole in men with balanitis.
29. Study Report, Protocol FCA-NY-90-012, An open, multicenter, comparative study of the efficacy and safety of fluconazole compared to clotrimazole in the treatment of patients with *Candida* balanitis.
30. Brammer KW, Multicentre Study Group. Treatment of vaginal candidiasis with a single oral dose of fluconazole. *Eur J Clin Microbiol Infect Dis.* June 1988; 7(3):364-367.
31. Osinus BO, Rotowa NA. Fluconazole as single-dose treatment of vulvo-vaginal candidosis. *Curr Ther Res.* June 1988; 43(6):1014-1018.
32. Fluconazole Capsules IRD. Volume 4.3. May 1987; Protocol 321. pp. 520-591.
33. Fluconazole Capsules IRD. Volume 4.3. May 1987; Protocol 322. pp. 603-647.
34. Fluconazole Capsules IRD. Volume 4.4. May 1987; Protocol 326. pp. 771-795.
35. Fluconazole Capsules IRD. Volume 4.4. May 1987; Protocol 327. pp. 831-857.

36. Fluconazole IRD. Volume 4.7. August 1988; Protocol 111. pp. 1444-1510.
37. Fluconazole IRD. Volume 4.7. August 1988; Protocol 348. pp. 1512-1640.
38. Study Report, Protocol FCA-NY-90-011, An open study of the efficacy and safety of fluconazole in the treatment of patients with onychomycosis.
39. Study Report, Protocol FCA-SF-91-001, A non-comparative study of the efficacy and safety of fluconazole in the treatment of patients with onychomycosis.
40. Fluconazole Dermal IRD Supplement, Pfizer Central Research, Sandwich. May 1988.
41. Study Report, Protocol FCA-LA-VEN-94-001, Protocol FCA-LA-BRA-94-001A, Protocol FCA-LA-ERU-94-001A, Protocol FCA-LA-AR-94-001B, Protocol FCA-LA-BRA-94-001B, Protocol FCA-LA-VEN-94-002, Protocol FCA-LA-COL-94-002C and Protocol FCA-LA-COL-94-003A, Three Open Comparative Studies of Efficacy and Safety of Fluconazole and Ketoconazole, Itraconazole, or Clotrimazole in the Treatment of Patients with Pityriasis Versicolor.
42. Study Report, Protocol FCA-NY-90-007, An Open Comparative Study of the Efficacy and Safety of Two Fluconazole Dosage Regimens and Itraconazole in the Treatment of Patients with Pityriasis Versicolor.
43. Study Report, Protocol FCA-EG-93-001, Efficacy and Toleration of Three Dosage Regimens of Fluconazole in Pityriasis Versicolor: An Open Multicenter Study.
44. Faergemann J, Treatment of Pityriasis Versicolor with a Single Dose of Fluconazole. *Acta Derm Venereol (Stockh)* 1992; 72: 74-75.
45. Diaz M, *et al.* A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. *Clin Inf Dis*, 1992. 14(Suppl. 1):68-76.
46. Pediatric IRD; Central Research, Sandwich, October 1993.
47. Study Report, Protocol 056-020, Phase I multiple dose study comparing the safety and disposition of oral fluconazole in normal volunteers to subjects with varying degrees of renal insufficiency.
48. Fluconazole Intravenous IRD. Vol. 1.2. August 1988; p.14.
49. Preliminary summary of terfenadine pharmacokinetics for Protocol No. R-0490, A multiple-dose study to determine the potential interaction of fluconazole, 400 and 800 mg, with terfenadine in healthy subjects.
50. Honig PK *et al.* The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. *Clin Pharm Ther.* 1993; 53:630-636.
51. Preliminary fluconazole-cisapride interaction study report: Protocol 056-035: A multiple-dose study to determine the potential interaction of fluconazole 200, 400 and 800 mg with cisapride in healthy subjects.
52. Safety Report. Fluconazole and Cisapride drug interaction: An update, March 6, 1997.
53. Safety Report. Fluconazole and Hepatic Events, June 16, 1993.
54. Safety Report. Fluconazole and Adverse Hepatic Events: An Update, May 12, 1998.

55. Safety Report. Fluconazole and Bullous/Exfoliative Adverse Skin Reactions, April 27, 1994.
56. Norris E. Serious adverse effect/fluconazole, memorandum to distribution, August 1, 1988.
57. Adverse reaction report and clinical summary of anaphylaxis occurring after administration of the antifungal agent fluconazole.
58. Van Dyke CPG, Veerman ER and Haverkamp MCM. Anaphylactic reactions to ketoconazole. *Br Med J.* 1983; 287:1673.
59. Fainstein V, Bodey GP. Cardio-respiratory toxicity due to miconazole. *Ann Intern Med.* 1980; 93:432-433.
60. Fluconazole IRD. Volume 4.3. August 1988; Protocol 233. pp. 327-361.
61. Smith AG. Potentiation of Oral Anticoagulants by ketoconazole. *British Medical Journal*, 21 January 1984; 288: p.188-189.
62. Yeh J. et. al. Potentiation of action of warfarin by itraconazole. *British Medical Journal*, 29 September 1990; 301: p.669.
63. Shenfield GM et. al. Potentiation of warfarin action by miconazole oral gel. *Aust. NJ. J. Med.* 1991; 21: p. 928.
64. Safety Report. Fluconazole and Warfarin Drug Interaction, July 28, 1999.
65. Safety Report. Fluconazole and Benzodiazepines (Short Acting), May 3, 1999.
66. Safety Report. Fluconazole and Dizziness, April 5, 1999.
67. Safety Report. Fluconazole and Dyspepsia, April 15, 1999.
68. Safety Report. Fluconazole and Vomiting, April 15, 1999.
69. Safety Report. Fluconazole and Angioedema, April 15, 1999.
70. Safety Report. Fluconazole and Face Edema, April 15, 1999.
71. Safety Report. Fluconazole and Pruritus, April 23, 1999.
72. Safety Report. Fluconazole and Hypercholesterolemia, April 5, 1999.
73. Safety Report. Fluconazole and Hypertriglyceridemia, May 18, 1999.
74. Safety Report. Fluconazole and Hypokalemia, April 5, 1999.
75. Safety Report. Fluconazole and Taste Perversion, April 23, 1999.
76. Safety Report. Fluconazole and Overdosage, April 23, 1999.
77. Safety Report. Fluconazole and Overdosage, November 7, 1996.



78. Olkkola KT, and Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. *Anesth Anaolog.*, 1996: 82: p. 511-516.
79. Ahonen J, Olkkola KT, and Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. *Eur J Clin Pharmacol.*, 1997: 51: p. 415-419.
80. Mesure R. Protocol 245. An open placebo-controlled crossover study to determine any effect of concomitant diuretic treatment on fluconazole pharmacokinetics in healthy volunteers.
81. Fluconazole Capsules IRD. Volume 4.2. May 1987; Protocol 217. pp. 421-460.
82. Fluconazole Capsules IRD. Volume 4.2. May 1987; Protocol 210. pp. 385-418.
83. Fluconazole Capsules IRD. Volume 5. May 1987; Part IVB.4, Section 3.8.2; p. 35.
84. Mesure R, Vierendeel Y. Protocol 056-244. A two-way, double-blind, placebo-controlled, crossover study to investigate the effect of orally administered fluconazole (200 mg daily) on the plasma concentration profile of an oral contraceptive in healthy female volunteers.
85. Schentag JJ, Blum RA, Harrison NJ. Protocol 007. Phase I study of the effect of fluconazole on the disposition of phenytoin.
86. Safety Report. Fluconazole and Rifabutin drug interaction, July 18, 1997.
87. Gerber N. Protocol 008. Phase I study of the effect of concomitant rifampin therapy on the disposition of fluconazole.
88. Fluconazole IRD. Volume 4.2. August 1988; Protocol 226A. pp. 98-133.
89. Mesure R. Protocol 238. A volunteer-blind, placebo-controlled study to assess potential interaction between fluconazole and chlorpropamide in healthy male volunteers.
90. Mesure R. Protocol 236. A volunteer-blind, placebo-controlled study to assess potential interaction between fluconazole and glibenclamide in healthy male volunteers.
91. Mesure R. Protocol 237. A volunteer-blind, placebo-controlled study to assess potential interaction between fluconazole and glipizide in healthy male volunteers.
92. Safety Report. Fluconazole and Tacrolimus drug interaction, July 14, 1997.
93. Final Study Report, Protocol 056-015. Hunt TL, Adams MA, Holmes GB. Phase I study of the effect of chronically administered fluconazole on the clearance of theophylline in normal healthy volunteers.
94. Sahai J, *et al.* Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. *JID* 1994; 169:1103-1107.
95. Safety Report. Fluconazole and Astemizole drug interaction, January 16, 1997.
96. Fluconazole Capsules IRD. Volume 4.1. May 1987; Protocol 203. pp. 85-102.

97. Fluconazole IRD. Volume 4.3. August 1988; Protocol 004. pp. 455-467.
98. Powles RL. Protocol 234. A study to assess the absorption and pharmacokinetics of oral fluconazole in subjects who have undergone autologous bone marrow transplantation.
99. Mesure R. Protocol 242. An open two-way crossover study to investigate the pharmacokinetics of 100 mg fluconazole when administered as a single oral dose alone or with antacids in healthy volunteers.
100. Safety Report. Fluconazole and Congenital Abnormalities, May 30, 1996.
101. Fluconazole: R63037: Embryotoxicity and Teratogenicity study in Sprague-Dawley Rats.
102. Fluconazole NDA. Volume 1.7. December 30, 1992. pp. 363-479.
103. Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. *Amer J Med.* Oct. 1988; 85:481-489.
104. Safety Report. Fluconazole and Headache, April 28, 1994.
105. Safety Report. Fluconazole and Seizures, April 28, 1994.
106. Safety Report. Fluconazole and Alopecia, April 26, 1994.
107. Safety Report. Fluconazole and Leukopenia, January 21, 1994.
108. Safety Report. Fluconazole and Thrombocytopenia, January 27, 1994.
109. Safety Report. Fluconazole and Agranulocytosis and Neutropenia, September 14, 1995.
110. CIOMS Suspect Adverse Reaction Report #RIC790, November 22, 1993.
111. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. *Antimicrob Agents Chemother.* Nov. 1985; 28(5):648-653.
112. Fluconazole Capsules IRD. Volume 3. May 1987; Part IIG, Study 14. pp. 1790-1800.
113. Fluconazole Capsules IRD. Volume 4.2. May 1987; Protocol 208. pp. 291-351.
114. Fluconazole Capsules IRD. Volume 5. May 1987; Section 3.6. pp 33-34.
115. Marriott MS, Pye GW, Richardson K, *et al.* The activity of fluconazole (UK-49,858), a novel bis-triazole antifungal and ketoconazole against fungal and mammalian sterol C14 demethylases. In: Iwata K, Bossche H Vanden, eds.: *In vitro and in vivo evaluation of antifungal agents*, Amsterdam, Elsevier, 1986:143-146.
116. Fluconazole Capsules IRD. Volume 3. May 1987; pp. 1598-1603, 1641-1644.
117. Bille, J, Glauser, M.P., and the Fluconazole Global Susceptibility Study Group. Evaluation of the susceptibility of Pathogenic *Candida* Species to Fluconazole *Eur. J. Clin. Microbiol. Infect. Dis.*, Dec. 1997; 16(12):924-928.

118. Rex, J, Rinaldi, M.G, Pfaller, M.A. Resistance to Candida Species to Fluconazole. *Antimicrobial Agents and Chemotherapy*, Jan. 1995:1-8.
119. Houston JB, Humphrey MJ, Matthew DE, *et al.* Comparison of two azole antifungal drugs, ketoconazole and fluconazole, as modifiers of rat hepatic mono-oxygenase activity. *Biochem Pharmacol.* 1988; 37(3):401-408.
120. Fluconazole Capsules IRD. Volume 4.1. May 1987; Protocol 205. pp. 168-203.
121. Hanger DP, Jevons S, Shaw JTB. Fluconazole and testosterone: In vivo and in vitro studies. *Antimicrob Agents Chemother.* May 1988; 32(5):646-648.
122. Fluconazole Capsules IRD. Volume 4.2. May 1987; Protocol 209. pp. 353-382.
123. Purba HS, Back DJ. Effect of fluconazole (UK-49,858) on antipyrine metabolism. *Brit J Pharmacol.* 1986; 21:603.
124. Fluconazole Capsules IRD. Volume 3. May 1987; Study 4. pp. 1703-1710.
125. Fluconazole Capsules IRD. Volume 3. May 1987; Study 6. pp. 1718-1723.
126. DeFernandez EP, Patino MM, Graybill JR, *et al.* Treatment of cryptococcal meningitis in mice with fluconazole. *J Antimicrob Chemother.* 1986; 18(2):261-270.
127. Fluconazole Capsules IRD. Volume 4.1. May 1987; Protocol 201. pp. 32-61.
128. Fluconazole Capsules IRD. Volume 4.2. May 1987; Protocol 207. pp. 236-282.
129. Fluconazole Capsules IRD. Volume 4.1. May 1987; Part IVA, Protocol 206. pp. 207-233.
130. Foulds G, Wajszczuk C, Weidler DJ, *et al.* Steady state parenteral kinetics of fluconazole in man. In: Georgiev VS, ed.: *First International Conference on Drug Research in Immunologic and Infectious Diseases. Antifungal drugs: Synthesis, preclinical and clinical evaluation.* Garden City, NY, Oct. 8-10, 1987. New York Academy of Science: 1987; p.6.
131. Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. *Antimicrob Agents Chemother.* April 1986; 29(4):579-583.
132. Fluconazole Capsules IRD. Volume 4.1. May 1987; Part IVA, Protocol 204. pp. 104-165.
133. Fluconazole Capsules IRD. Volume 4.3. August 1988; Protocol 001. pp. 363-391.
134. Fluconazole Capsules IRD. Volume 4.3. August 1988; Protocol 003. pp. 394-434.
135. Marriott MS, Humphrey MJ, Tarbit MH. UK-49,858: A new triazole antifungal drug with novel pharmacokinetics properties in laboratory animals. In: Ishigami J, ed.: *Recent Advances in Chemotherapy.* Tokyo, University of Tokyo Press: 1985; 1934-1935.

136. Richardson K, Andrews RJ, Marriott MS, *et al.* Correlation of in vitro and in vivo activity of azole antifungals. In: Iwata K, Bossche H Vanden, eds.: In vitro and in vivo evaluation of antifungal agents, Amsterdam, Elsevier, 1986:147-149.
137. Fluconazole Capsules IRD. Volume 4.2. August 1988; Part IVA, Protocol 228. pp. 226-253.
138. Faergemann J and Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without corneum) and eccrine sweat. Clin Exper Derm. 1993; 18:102-106.
139. Study Report, Protocol FCA-MACK-93-003, Pharmacokinetics of fluconazole in human plasma and saliva - Comparison of capsule and oral suspension.
140. Fluconazole IRD, Volume 1 of 3, Pediatric Claim: p. 36-43.
141. Fluconazole IRD-2, August 1988, Volume 3.5. pp. 1348 and 1350.
142. Fluconazole IRD-1, May 1987, Volume 2.4. p. 1564.
143. Fluconazole IRD-2, August 1988, Volume 3.5. p. 1335.
144. Fluconazole IRD-1, May 1987, Volume 2.4. p. 1165.
145. Fluconazole IRD-2, August 1988, Volume 3.5. pp. 1264 and 1392.
146. Safety Report. Fluconazole and Urticaria, November 30, 2001.
147. Safety Analysis Report: QT Prolongation and *Torsades de Pointes* Reported with Fluconazole. Report date: 27 June 2003.
148. Final Study Report: Protocol 066-086. A Study to Assess the Effect of Co-administration of a 1200 mg Dose of Azithromycin on the Pharmacokinetics of Fluconazole. Report date: 7 January 1999.
149. Final Study Report: Protocol 056-034. A Multiple-Dose Study to Determine the Potential Interaction of Fluconazole 200, 400 and 800 mg with Cisapride in Healthy Subjects. Report date: 16 August 2000.
150. Tett S, Moore S, Ray J. Pharmacokinetics and Bioavailability of Fluconazole in Two Groups of Males with Human Immunodeficiency Virus (HIV) Infection Compared with Those in a Group of Males without HIV Infection. Antimicrobial Agents and Chemotherapy. Aug. 1995, p. 1832-1841 Vol. 39, No. 8.
151. Study Report: Protocol 212. An Open Non-Comparative Study to Assess the Safety, Toleration and Pharmacokinetics of Fluconazole Administration as a Single 50 mg Oral Dose in Elderly Subjects and to Determine any Effect of Concomitant Diuretic Therapy.
152. Khazan M & Mathis AS: Probable cause of torsades de pointes induced by fluconazole. Pharmacotherapy 2002; 22(12):1632-1637.
153. C. Fasano J, O'Keeffe, D: Gibbs, Fluconazole Treatment of Neonates and Infants with Severe Fungal Infections Not Treatable with Conventional Agents. Eur. J. Clin. Microbiol. Infect. Dis. Vol. 13, 1994 351-354.

154. 2.5 Clinical Overview: To support updates to sections 4.4 and 4.6 of the Fluconazole CDS, November 2016.
155. Wassmann S, Nickenig G & Bohm M: Long QT syndrome and *torsade de pointes* in a patient receiving fluconazole. *Ann Intern Med* 1999; 131:797.
156. Wells C, Lever AML. Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. *J Infect* 1992; 24: 111-12.
157. Jacobson MA, *et al.* Fatal acute hepatic necrosis due to fluconazole. *Am J Med* 1994; 96: 188-90.
158. Holmes J, Clements D. Jaundice in HIV positive haemophiliac. *Lancet* 1989; i: 1027.
159. Franklin IM, *et al.* Fluconazole-induced jaundice. *Lancet* 1990; 336: 565.
160. Bronstein J-A, *et al.* Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. *Clin Infect Dis* 1997; 25: 1266-7.
161. Debruyne D, Ryckelynek J-P. Clinical pharmacokinetics of fluconazole. *Clin Pharmacokinet* 1993; 24: 10-27.
162. Indiana University School of Medicine, Division of Clinical Pharmacology: <http://medicine.iupui.edu/clinpharm/DDIs/table.asp>. Accessed May 7, 2009.
163. EMEA Volume 3 B Guidelines, Excipients in the label and package leaflet of medicinal products for human use, July 2003.
164. Gondo H, Okamura C, Shimoda K *et al*: Acquired Pelger-Huet anomaly in association with concomitant tacrolimus and fluconazole therapy following allogenic bone marrow transplantation. *Bone Marrow Transplant* 2000; 26:1255-57.
165. Manez R, Martin M, Raman V *et al*: Fluconazole therapy in transplant recipients receiving FK506. *Transplantation* 1994; 52:1521-23.
166. Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA: Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. *J Pharmacol Exp Ther.* 1998 May; 285(2):428-37.
167. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT: The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. *Anesth Analg* 1998; 87:190-194.
168. Duggal HS: *Gen Hosp Psychiatry* 2003; 25:297-298; Delirium associated with amitriptyline/fluconazole drug.
169. Gannon RH, Anderson ML: *Ann Pharmacother* 1992; 26:1456-1457; Fluconazole-nortriptyline drug interaction.
170. Newberry DL, Bass SN, Mbanefo CO: *Clin Infect Dis* 1997; 24:270-271; A fluconazole/amitriptyline drug interaction in three male adults.

171. Robinson RF, Nahata MC, Olshefski RS: Ann Pharmacother 2000; 34:1406-1409; Syncope associated with concurrent amitriptyline and fluconazole therapy.
172. Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick V: Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis. 1994 Aug; 170(2):384-9.
173. Shen WW: Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Int J Psychiatry Med 1995; 25:277-290.
174. Slaughter RL & Edwards DJ: Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29:619-624.
175. Varhe A, Olkkola KT & Neuvonen PJ: Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996; 42:465-470.
176. Albengres E, Le Louet H, Tillement JP: Drug Saf 1998; 18:83-97; Systemic antifungal agents. Drug interactions of clinical significance.
177. Finch CK, Green CA, Self TH; South Med J 2002; 95:1099-1100; Fluconazole-carbamazepine interaction.
178. Ketter Tax, Post RM, Worthington K: J Clin Psychopharmacol 1991; 11:306-313; Principles of clinically important drug interactions with carbamazepine. Part II.
179. Spina E, Pisani F, Perucca E: Clin Pharmacokinet 1996; 31:198-214; Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
180. Ulivelli M, Rubegni P, Nuti D, Bartalini S, Giannini F; Rossi S: J Neurol 2004;251:622-623; Clinical evidence of fluconazole-induced carbamazepine toxicity.
181. Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000 Mar; 38(3):225-42.
182. Canafax DM, Graves NM, Hilligoss DM *et al*: Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study. Transplant Proc 1991; 23:1041-1042.
183. Collignon P, Hurley B & Mitchell D: Interaction of fluconazole with cyclosporin. Lancet 1989; 1:1262.
184. Kruger HU, Schuler U, Zimmermann R *et al*: Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989; 24:781-786.
185. Gil JA: Fluconazole-cyclosporine interaction: a dose-dependent effect' Ann Pharmacother 1993; 27:427-430.
186. Sud K, Singh B, Krishna VS *et al*: Unpredictable cyclosporin-fluconazole interaction in renal transplant recipients. Nephrol Dial Transplant 1999; 14:1698-1703.
187. Sugar AM, Saunders C, Idelson BA *et al*: Interaction of fluconazole and cyclosporine. Ann Intern Med 1989; 110:844.

188. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M; McDonald GB: Transplantation 2004;103:1557-1559; Cyclophosphamide metabolism is affected by azole antifungals.
189. Hallberg P, Marten L, Wadelius M: 2006; 62(6): 491-492-492; Possible fluconazole-fentanyl interaction - A case report.
190. Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT: Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol. 2008 Jan;64(1):25-30. Epub 2007 Nov 7.
191. [Mercadante S](#), [Villari P](#), [Ferrera P](#): Itraconazole-fentanyl interaction in a cancer patient. [J Pain Symptom Manage](#). 2002 Sep;24(3):284-6.
192. B. Baune JP, Flinois V, Furlan F, Gimenez AM, Taburet L, Becquemont, Farinotti R: Halofantrine Metabolism in Microsomes in Man: Major Role of CYP 3A4 and CYP 3A5, Journal of Pharmacy and Pharmacology, Volume 51, Number 4, 1 April 1999 , pp. 419-426(8).
193. Gilad R; Lampl Y; Clin Neuropharmacol 1999;22:295-297; Rhabdomyolysis induced by simvastatin and ketoconazole treatment.
194. Horn M; Arch Dermatol 1996; 132:1254; Co-administration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.
195. Kahri J; Valkonen M; Backlund T; Vuoristo M; Kivisto KT; Eur J Clin Pharmacol 2005;60:905-907; Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.
196. Kantola T; Kivisto KT; Neuvonen PJ; Clin Pharmacol Ther 1998c;64:58-65; Effect of itraconazole on the pharmacokinetics of atorvastatin.
197. Shaukat A; Benekli M; Vladutiu GD; Slack JL; Wetzler M; Baer MR; Ann Pharmacother 2003;37:1032-1035; Simvastatin-fluconazole causing rhabdomyolysis.
198. Kantola T, Backman J, Niemi M, Kivisto K, Neuvonen P. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56:225-9.
199. European Commission Notice to Applicants: A Guideline on Summary of Product Characteristics, Revision 1, 2005.
200. Gupta AK; Katz HI; Shear NH; J Am Acad Dermatol 1999;41:237-249; Drug interactions with itraconazole, fluconazole, and terbinafine and their management.
201. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000 Feb; 38(2):111-80.
202. Kaukonen KM; Olkkola KT; Neuvonen PJ; Eur J Clin Pharmacol 1998;53:445-449; Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
203. Cobb MN; Desai J; Brown LS; Zannikos PN; Rainey PM; Clin Pharmacol Ther 1998;63:655-662; The effect of fluconazole on the clinical pharmacokinetics of methadone.

204. Liu P; Foster G; LaBadie R; Somoza E; Sharma A; *Antimicrob Agents Chemother* 2007;51(1): 110-118-118; Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
205. Tarumi Y; Pereira J; Watanabe S. *J Pain Symptom Manage*, 2002;23:148-153; Methadone and fluconazole: respiratory depression by drug interaction.
206. Greenblatt DJ; von Moltke LL; Perloff ES; Luo Y; Harmatz JS; Zinny MA; *Clin Pharmacol Ther* 2006a; 79:125-133; Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies.
207. Hynninen V; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Vyyrylainen H; Laine K; *Antimicrob Agents Chemother* 2006;50(6): 1967-1972-1972; Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of S-(+)- and R-(-)-ibuprofen.
208. Tiao GM, Martin J, Weber FL, Cohen RM, Hanto DW. Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. *Clin Transplant*. 1999 Feb;13(1 Pt 1):62-4.
209. Narang PK, Trapnell CB, Schoenfelder JR *et al*. Fluconazole and enhanced effect of rifabutin prophylaxis. *NEJM* 1994 Vol 330, No 18, pg. 1316.
210. Koks CH; Crommentuyn KM; Hoetelmans RM; Burger DM; Koopmans PP; Mathot RA; Mulder JW; Meenhorst PL; Beijnen JH; *Br J Clin Pharmacol* 2001;51:631-635; The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
211. MacKenzie-Wood AR; Whitfeld MJ; Ray JE; *Med J Aust* 1999;170:46-47; Itraconazole and HIV protease inhibitors: an important interaction.
212. Cervelli MJ; *Transplantation* 2002;74:1477-1478; Fluconazole-sirolimus drug interaction.
213. Kuypers DR; Claes K; Evenepoel P; Maes B; Vandecasteele S; Vanrenterghem Y; Van DB; Desmet K; *Transplantation* 2005;79:737; Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient.
214. Sadaba B; Campanero MA; Quetglas EG; Azanza JR; *Transplant Proc* 2004;36:3226-3228; Clinical relevance of sirolimus drug interactions in transplant patients.
215. Said A; Garnick JJ; Dieterle N; Peres E; Abidi MH; Ibrahim RB; *Pharmacotherapy* 2006;26:289-295; Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient.
216. Vanier KL; Mattiussi AJ; Johnston DL; *J Pediatr Hematol Oncol* 2003;25:403-404; Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukaemia.
217. Sampol E, *et al*. Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. *Br J Clin Pharmacol* 1995; 40: 83-6.
218. Clinical Overview to support the July CDS revision – Drug Interactions, August 5, 2009.
219. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K; Stein CM: *N Engl J Med* 2004;351:1089-1096; Oral erythromycin and the risk of sudden death from cardiac causes.



220. Peters RW, Gold MR: The Influence of Gender on Arrhythmias. *Cardiology in Review*. 2004;12(2):97-105.
221. Pfizer Study Report, Protocol 231: Assessment of the effect of impaired renal function on the pharmacokinetics of fluconazole administered as a single 50 mg oral dose, January 1989.
222. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. *Am J Med Genet* 1997; 72(3):253-6.
223. Banks, L. Medicines Q&As: Can oral fluconazole be used during pregnancy?  
<http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Q--A/Can-oral-fluconazolebeused-during-pregnancy>
224. Carey JC, Martinez L, Balken E, *et al*. Determination of Human Teratogenicity by the Astute Clinician Method: Review of Illustrative Agents and a Proposal of Guidelines. *Birth Defects Res PT A* 2009; 85(1):63-68.
225. Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis: a prescription-event monitoring study, with special reference to the outcome of pregnancy. *Eur J Clin Pharmacol* 1994; 46(2):115-8.
226. Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. *Pharmacotherapy* 1999; 19(2):221-2.
227. Lee BE, Feinberg M, Abraham JJ, *et al*. Congenital malformations in an infant born to a woman treated with fluconazole. *Pediatr Infect Dis J* 1992; 11(12):1062-4.
228. Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype. *Birth Defects Res* 2005; 73(11):919-23.
229. Mastroiacovo P, Mazzone T, Botto LD, *et al*. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. *Am J Obstet Gynecol* 1996; 175(6):1645-50.
230. Norgaard M, Pedersen L, Gislum M, *et al*. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. *J Antimicrob Chemother* 2008; 62(1):172-6.
231. Pursley TJ, Blomquist IK, Abraham J, *et al*. Fluconazole-induced congenital anomalies in three infants. *Clin Infect Dis* 1996; 22(2):336-40.
232. Rubin PC, Wilton LV, Inman WHW. Fluconazole and pregnancy: results of a prescription event-monitoring study. *Int J Gynaecol Obstet* 1992; 37(Suppl 1):25-7.
233. Sanchez JM, Moya G. Fluconazole teratogenicity. *Prenat Diagn* 1998; 18(8):862-3.
234. Sorensen HT, Nielsen GL, Olesen C, *et al*. Risk of malformations and other outcomes in children exposed to fluconazole *in utero*. *Br J Clin Pharmacol* 1999; 48(2):234-8.
235. Pfizer Study Report, Protocol A1501065: An open, randomised, two-way crossover study to investigate the effects of multiple dose fluconazole on the steady state pharmacokinetics of voriconazole in healthy male volunteers, February, 2005.

236. Pfizer Study Report, Protocol A1501074: An open label, multiple dose study to investigate the effects of fluconazole on the pharmacokinetics of voriconazole in healthy male volunteers, August 2006.
237. 2.5 Clinical Overview for Fluconazole: Drug-Drug Interaction with Tofacitinib, February, 2013.
238. 2.5 Clinical Overview for Fluconazole: Addition of Dosing Recommendation for Tofacitinib Concomitant Medication, March, 2013.
239. 2.5 CLINICAL OVERVIEW: To Support Updates to the Fluconazole CDS and any Other Applicable Product Information April 2013.
240. 2.5 Clinical Overview: To support update to the Fluconazole CDS - CYP2C19, October 2013.
241. 2.5 Clinical Overview: To Support Updates to the Core Data Sheet, March 2017.
242. 2.5 Clinical Overview: To Support the Addition of Interaction for Co-Administration of Fluconazole with Olaparib to Section 4.5 Interaction with other Medicinal Products and other Forms of Interaction to the Core Data Sheet, February 2017.
243. 2.5 Clinical Overview: To Support Updates to Section 4.2, Section 4.4 and Section 4.5 of the Core Data Sheet, August 2017.
244. 2.5 Clinical Overview: To Support Update to Section 4.5 Interaction with other Medicinal Products and other Forms of Interaction of the Core Data Sheet, January 2020.
245. 2.5 Clinical Overview: To Support Update to Section 4.5 Interaction with other Medicinal Products and other Forms of Interaction of the Core Data Sheet, March 2020.
246. 2.5 Clinical Overview: To Support Update to Section 5.1 Pharmacodynamic Properties of the Core Data Sheet, April 2020.
247. 2.5 Clinical Overview: To Support Update to Section 4.5 Interaction with other Medicinal Products and other Forms of Interaction of the Core Data Sheet, October 2020.